ΛΟΙΜΩΞΗ HIV. Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική
|
|
- Albert Wilkins
- 6 years ago
- Views:
Transcription
1 ΛΟΙΜΩΞΗ HIV Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική Κλινική, Νοσοκομείο «Αττικόν»
2
3 Infection
4 Acute Myocardial Infarction p er 100,000 HIV/AIDS discharg es Source: SPARCS database, NYSDOH
5 MI and HIV duration Mary-Krause et al, AIDS, 2003
6 HIV AND CARDIOVASCULAR RISK FACTORS Lipid abnormalities Lipodystrophy Insulin resistance Inflammation Changes in renal function
7 CAUSES OF METABOLIC ABNORMALITIES Effects of a chronic inflammatory conditions Medication effects Changes in body composition
8 EFFECTS OF HAART
9 Lipid abnormalities HDL LDL VLDL OxLDL Small, dense LDL
10 Lipodystrophy Loss of subcutaneous fat Relative preservation of visceral fat Preservation of dorsocervical fat (buffalo hump) Fat in the breasts
11 Brown TT et al. Arch Intern Med 2005;165:
12 Insulin resistance Drug-induced Increased visceral fat-inflammation Inhibition of mitochondrial function in muscle
13 HAART EFFECTS Hypertriglyceridemia (40-80%) Hypercholesterolemia (10-50%) Mixed forms (10-40%) Hyperinsulinemia-Insulin resistance (30-40%) Diabetes-Positive OGTT (10-15%) 15%)
14 EPIDEMIOLOGICAL EVIDENCE FOR CARDIOVASCULAR DISEASE Retrospective cohort studies Clinical databases Prospective HIV cohort studies Randomized clinical trials
15 Surrogate markers of atherosclerosis 8,00 F=11.7, p<0.01 7,07 0,75 F=4.2, p=0.01 0,64 0,66 6,00 FMD (%) 5,43 IMT (mm) 0,55 0,50 4,00 2,00 2,76 0,25 0,00 HIV CAD NORMAL HIV CAD NORMAL HAART related with increased IMT Lekakis J Ikonomidis I et al, Clin Science,2008
16 Lekakis J Ikonomidis I et al, Clin Science,2008
17 Reactive hyperemia Lekakis J Ikonomidis I, Microcirculation 2010
18 Carotid atherosclerosis: HIV+HAART Study population Features studied Endpoints Lekakis et al. (Clin Sci. 2008) 71 HIV 29 CAD 25 healthy IMT Metabolic parameters Increased IMT was closely related to protease inhibitor related changes of metabolic parameters in HIV infected patients Hsue et al. (AIDS. 2009) 368 HIV 93 healthy 33 HIV controls IMT Infection and immune parameters Chronic inflammation as reflected by elevated CRP levels in all HIV infected patients, may account for early atherosclerosis PERI study (Coron Artery Dis. 2008) 83 HIV 83 healthy IMT Cardiovascular risk factors HIV infection was associated with increased IMT and elevated prevalence of cardiovascular risk factors Lorenz et al. (Atherosclerosis. 2008) 292 HIV 1168 healthy IMT Infection and therapy parameters HIV infection and HAART are independent risk factors for early carotid atherosclerosis. Vascular risk is 4 14% greater and the "vascular age" 4 5 years higher in HIV positive subjects compared to healthy controls Jerico et al. (Stroke. 2006) 68 HIV 68 HIV with CVD risk factors HAART HAART should be considered a strong, independent predictor for the development of subclinical atherosclerosis in HIV infected patients
19 Endothelial dysfunction: HIV+HAART Charakida et al. (Circulation. 2005) Lekakis et al. (Clin Sci. 2008) Solages et al. (Clin. Infect. Dis. 2006) Flammer et al. (Heart. 2009) Study population 83 HIV children 59 healthy children 71 HIV 29 CAD 25 healthy 75 HIV 223 healthy Features studied FMD HAART Infection parameters FMD Metabolic and disease parameters FMD Metabolic and disease parameters 39 HIV HAART regimens Endpoints HIV infection in childhood is associated with adverse structural and functional vascular changes that are most pronounced in children exposed to PI therapy HAART induced lipid disorders may lead to endothelial dysfunction in HIV patients HAART induced lipid disorders may lead to endothelial dysfunction in HIV patients HAART regimens affect vascular function through a combination of atherogenic lipid profiles and direct detrimental effects on endothelium
20 HIV and vascular function HIV (+) without HAART HIV (+) withhaart Hypertensive PWV (m/sec) Lekakis J Ikonomidis I et al Am J Hypertens 2009
21
22 Patients naïve to HAART Vlachopoulos et al Artery Res 2009
23 Vlachopoulos et al Artery Res 2009
24 N=2789 Seaberg et al Stroke. 2010;41:
25 Seaberg et al Stroke. 2010;41:
26 Arterial stiffness: HIV INFECTION+HAART Lekakis et al. (Am J Hypertens. 2009) Schillaci et al. (Arterioscer Thromb Vasc Biol. 2005) Van Vonderen et al. (J AIDS. 2009) Schillaci et al. (Hypertension. 2001) Vlachopoulos et al (Artery Res 2009) Study population 56 HIV 28 hypertensives 28 healthy 32HIV 32 healthy 77 HIV 52 healthy 39 HIV 78 healthy 51 adults 35 healthy Features studied PWV Metabolic parameters PWV Infection parameters Arterial stiffness Arterial stiffness Infection PWV,wave reflection HAARTnaïve` Endpoints HIV patients on HAART had similar PWV with hypertensives. Patients on HAART had higher PWV than patients without. HIV infection and age predict higher PWV values HIV infection was associated with increased arterial stiffness HIV infection is an independent risk factor for worse arterial stiffness In the early stages of HIVinfection,decreased wave reflections and similar aortic stiffness, in HAARTnaive patients than controls. Sevastianova et al. (Antivir Ther. 2005) 59 HIV Arterial stiffness HAART The use of PI s predicts abnormal arterial stiffness
27 MI EXPOSURE TO HAART N= DAD Study Group. N Engl J Med 2007;356:
28 DAD Study Group. N Engl J Med 2007;356:
29 DAD Study Group. Lancet 2008; 371:
30 Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk. Augmentation index (AI) in 20 men who switched from abacavir to tenofovir. After 4 weeks, reduction of mean AI from 22% by 4% (P = 0.03) Framingham risk score by 2% (P = 0.01), which was driven by lower total cholesterol (0.8 mmol/l; ; P = 0.002). Consistent trends were observed through week 24. Abacavir may impair cardiovascular function by increasing total cholesterol levels. Sinn et al AIDS Sep 24;24(15):2403-5
31 SCREENING FOR CHD IN HIV PATIENTS Pretest likelihood for CHD Stress tests Newer inflammatory markers CRP, Adiponectin Surrogate markers IMT Coronary artery calcium scores
32 CHD RISK PREDICTION MODELS Framingham equation HIV-specific models
33 PREVENTION STRATEGIES Cigarette smoking Diabetes mellitus Dyslipidemia Mode of antiretroviral therapy
34
35 HYPERLIPIDEMIA TREATMENT IN HIV PATIENTS WITH HAART Elevated LDL or elevated non HDL with TG mg/dl Statin (B1) Pravastatin Atorvastatin Fluvastatin Alternatives Fibrate(C1) or Niacin (C3) Triglycerides >500mg/dl Fibrates(B1) Niacin or fish oils (C3)
36 AIDS Nov 28;20(18):2395-8
37 CONCLUSIONS HIV pts live longer owing to the success of antiretroviral therapy Cardiovascular disease now ranks as a major cause of death in this population Dyslipidemia, insulin resistance, inflammation and changes in body composition are likely to contribute to this These abnormalities are due to HIV infection, related inflammation or toxicities of HAART
38 CONCLUSIONS(II) Cardiovascular risk evaluation should be performed regularly in those pts Life style modifications should be encouraged Pharmacological treatment of dyslipidemia and diabetes is mandatory Maintaining virological suppression should be the main concern in HIV pts Development of optimized screening, prediction and treatment algorithms for CHD is of utmost importance
39
40
41
42 PREVENTION STRATEGIES QUESTIONS AND PRIORITIES FOR RESEARCH -Optimal cessation strategy for smoking -Optimal treatment strategy for dyslipidemia -Lifestyle intervention -Optimal antiretroviral therapy
43 La Pitie Institute, Paris
44
45 HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease. Lekakis J, Tsiodras S, Ikonomidis I, Palios J, Poulakou G, Rallidis L, Antoniadou A, Panagopoulos P, Papadopoulos A, Giamarellou H, Kremastinos DT. Clin Sci (Lond) Sep;115(6):
46
47
48 Grinspoon S. Circulation 2009;119:
49 HIV AND CARDIOVASCULAR RISK FACTORS Lipid abnormalities Lipodystrophy Insulin resistance Inflammation Changes in renal function
50 HIV AND CARDIOVASCULAR RISK FACTORS Lipid abnormalities Lipodystrophy Insulin resistance Inflammation Changes in renal function
51 HIV AND CARDIOVASCULAR RISK FACTORS Lipid abnormalities Lipodystrophy Insulin resistance Inflammation Changes in renal function
52 HIV AND CARDIOVASCULAR RISK FACTORS Lipid abnormalities Lipodystrophy Insulin resistance Inflammation Changes in renal function
53 Microalbuminuria 5 times more common
54
55
56 Hadigan C et al. Ann Intern Med 2004;140:786-94
57 HIV AND CARDIOVASCULAR RISK FACTORS QUESTIONS AND PRIORITIES FOR RESEARCH -Better identification of direct and indirect HIV effects on metabolic parameters -HIV-induced proatherosclerotic changes in lipoprotein structure Contribution of dyslipidemia and insulin resistance to cardiovascular disease -Identification of the mechanisms of body composition changes -Individual drug vs class effects
58 DAD Study Group. N Engl J Med 2007;356:
59 EPIDEMIOLOGICAL EVIDENCE QUESTIONS AND PRIORITIES FOR RESEARCH -Importance of appropriate control groups -Relative impact of traditional and nontraditional risk factors -Risk profile of drugs -Determination of the true risk
60 EFFECTS OF HIV AND THERAPY ON HEART AND VESSELS Left ventricular dysfunction Myocarditis Endothelial dysfunction Pulmonary hypertension Pericardial effusion
61 EFFECTS OF HIV AND THERAPY ON HEART AND VESSELS Left ventricular dysfunction Myocarditis Endothelial dysfunction Pulmonary hypertension Pericardial effusion
62 ECG abnormalities in ~60% LV dysfunction by Echo common Data from pre HAART era
63 EFFECTS OF HIV AND THERAPY ON HEART AND VESSELS Left ventricular dysfunction Myocarditis Endothelial dysfunction Pulmonary hypertension Pericardial effusion
64 MI EXPOSURE TO HAART DAD Study Group. N Engl J Med 2003;349:
65 AIDS-RELATED ACTIVE LYMPHOCYTIC MYOCARDITIS
66 HIV-ASSOCIATED DILATED CARDIOMYOPATHY
67 HIV-ASSOCIATED PERICARDIAL EFFUSION
68 Myocarditis 50% positive biopsy in the pre-haart era Endothelial dysfunction mildly improves with antiretroviral therapy Pulmonary hypertension in 1/200 pts Pericardial effusion 11% per year
69 HIV-ASSOCIATED CARDIAC TUMORS
70 HIV-ASSOCIATED PULMONARY HYPERTENSION
71 Barbaro G, J Respr Dis, 2004
72 HIV AND HEART-VESSELS QUESTIONS AND PRIORITIES FOR RESEARCH -Specific drug effects -Biomarkers for vascular and myocardial dysfunction -Development of effective treatment strategies
73 SCREENING IN HIV PATIENTS QUESTIONS AND PRIORITIES FOR RESEARCH -Identification of optimal screening strategy -Risk stratification algorithm -Sensitivity and specificity of diagnostic tests -Clinical utility of surrogate markers
74 CHD RISK PREDICTION MODELS QUESTIONS AND PRIORITIES FOR RESEARCH -Choice of end points -Development of an accurate risk prediction model
75 HIV AND CARDIOVASCULAR RISK FACTORS Lipid abnormalities Lipodystrophy Insulin resistance Inflammation Changes in renal function
76 HYPERGLYCEMIA THERAPY IN HIV PTS WITH HAART Sulfonylureas Biguanides Thiazolidinediones Insulin therapy
Hans Strijdom SA Heart Meeting November 2017
Hans Strijdom SA Heart Meeting November 2017 HIV-infection and ART, but not high sensitivity CRP, are associated with markers of vascular function: Results from the Western Cape cohort of the EndoAfrica
More informationHIV Infection as a Chronic Disease. Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School
HIV Infection as a Chronic Disease Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School Role of Primary Care Approximately 50,000 patients are diagnosed with HIV infection annually
More informationΗ σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις
Η σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις Ελένη Τριανταφυλλίδη Επιμελήτρια Α Β Πανεπιστημιακή Καρδιολογική Κλινική Αττικό Νοσοκομείο
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationHDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart
Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT
More informationPractical challenges in CV risk management: When to start intervening in CVD?
The National Research Center for Preventive Medicine Ministry of Healthcare, Russian Federation Practical challenges in CV risk management: When to start intervening in CVD? Prof. Drapkina O.M., Eliashevich
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACC/AHA. See American College of Cardiology/ ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors American College of Cardiology/American
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationLow grade inflammation and cardiovascular disease
Low grade inflammation and cardiovascular disease Konstantinos Aznaouridis, MD PhD 1 st Department of Cardiology Hippokration Hospital Athens Medical School Atherosclerosis Start from very young To Old
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationHIV and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Implications
HIV and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Implications Matthew J. Feinstein, MD, MSc Assistant Professor of Medicine Northwestern University Feinberg School of Medicine Chicago,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced
More informationIschemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection
HIV/AIDS MAJOR ARTICLE Ischemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection Max H. David, 1,3 Richard Hornung, 2 and Carl J. Fichtenbaum 1 1 Department of Medicine, Division
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationProf. John Chapman, MD, PhD, DSc
Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationD Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis, E Christoforatou, A Samentzas, A Siama, C Stefanadis
Peripheral Vessels Unit, 1st Department of Cardiology Athens Medical School Hippokration Hospital, Athens, Greece D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis,
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationImaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006
Imaging Biomarkers: utilisation for the purposes of registration EMEA-EFPIA Workshop on Biomarkers 15 December 2006 Vascular Imaging Technologies Carotid Ultrasound-IMT IVUS-PAV QCA-% stenosis 2 ICH E
More informationLow HDL-levels: leave it or treat it?
Cardiology Update 2011 Davos, 14 02 2011 Low HDL-levels: leave it or treat it? Experts: J.P. Kastelein, Amsterdam and U. Landmesser, Zurich Cases: C. Besler, Zurich and I. Sudano, Zurich Mr H.B., 1960
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More information10/17/16. Assessing cardiovascular risk through use of inflammation testing
Assessing cardiovascular risk through use of inflammation testing Anthony L. Lyssy, DO Medical Director and Managing Partner Diamond Physicians Dallas, TX Response to Injury Hypothesis Injury Response
More informationDyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Dyslipidemia and HIV Heidi Crane, MD, MPH Madison Metabolic Clinic Associate Professor UW Department of Medicine Presentation prepared by: Heidi Crane, MD,
More informationSanger Heart & Vascular Institute Symposium 2015
Sanger Heart & Vascular Institute Symposium 2015 Cardiovascular Update For Primary Care Physicians William E. Downey, MD FACC FSCAI Medical Director, Interventional Cardiology Sanger Heart & Vascular Institute
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationManagement of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?
Perspective Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin? Current guidelines for managing cholesterol to reduce cardiovascular disease (CVD)
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationWhat is Malnutrition?
HIV & Obesity Gail Shor-Posner, PhD Director, Division of Disease Prevention Department of Epidemiology & Public Health University of Miami Miller School of Medicine What is Malnutrition? Under-nutrition
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationPreclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD
Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD 1 Preclinical? No symptoms No physical findings No diagnostic ECG findings No chest X-ray X findings No diagnostic events 2
More informationCoronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationMetabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification
More informationHow to detect early atherosclerosis ; focusing on techniques
How to detect early atherosclerosis ; focusing on techniques Jang-Ho Bae, MD., PhD. Heart Center Konyang University Hospital Daejeon city, S. Korea Surrogates for Atherosclerosis Measures of endothelial
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationBeyond LDL-Cholesterol
Biomarkers for Risk Stratification Beyond LDL-Cholesterol Athanasios J.Manolis Director Cardioilogy Dep, Asklepeion Hospital, Athens, Greece Adj. Professor of Medicine, Emory University Atlanta, USA Adj.
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More informationC-Reactive Protein and Your Heart
C-Reactive Protein and Your Heart By: James L. Holly, MD Inflammation is the process by which the body responds to injury. Laboratory evidence and findings at autopsy studies suggest that the inflammatory
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationEyes on Korean Data: Lipid Management in Korean DM Patients
Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea Causes of Death in People
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More informationLipid Lowering in Patients at High Risk for Cardiovascular Disease
Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationHuman immunodeficiency virus
Panarteritis: beyond the vulnerable plaque Human immunodeficiency virus Stockholm, August 30, 2010 Giuseppe Schillaci Department of Clinical and Experimental Medicine University of Perugia Perugia, Italy
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationCardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009
Cardiovascular disease, studies at the cellular and molecular level Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009 Content Introduction The number 1 killer in America Some statistics
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationStatin Use and Cardiovascular Disease in HIV
Statin Use and Cardiovascular Disease in HIV Steven K. Grinspoon, MD Professor of Medicine Harvard Medical School Boston, Massachusetts FLOWED: 04/18/16 Los Angeles, California: April 25, 2016 Statin Use
More informationHIV and Cardiovascular Disease: Responding to the Risk
HIV and Cardiovascular Disease: Responding to the Risk Reprinted from The prn Notebook june 2004 Dr. James F. Braun, Editor-in-Chief Tim Horn, Executive Editor. Published in New York City by the Physicians
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationHeart Online First, published on March 29, 2005 as /hrt SCIENTIFIC LETTER
Heart Online First, published on March 29, 2005 as 10.1136/hrt.2004.056523 Manuscript ID: HEARTJNL/2004/056523 March 18, 2005 SCIENTIFIC LETTER Effects of HMG-CoA Reductase Inhibition on Endothelial Function
More information